[go: up one dir, main page]

TWI455721B - 癌疫苗組合物 - Google Patents

癌疫苗組合物 Download PDF

Info

Publication number
TWI455721B
TWI455721B TW97147299A TW97147299A TWI455721B TW I455721 B TWI455721 B TW I455721B TW 97147299 A TW97147299 A TW 97147299A TW 97147299 A TW97147299 A TW 97147299A TW I455721 B TWI455721 B TW I455721B
Authority
TW
Taiwan
Prior art keywords
peptide
serial number
gly glu
phe
ser val
Prior art date
Application number
TW97147299A
Other languages
English (en)
Other versions
TW200930402A (en
Inventor
杉山治夫
Original Assignee
癌免疫研究所股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 癌免疫研究所股份有限公司 filed Critical 癌免疫研究所股份有限公司
Publication of TW200930402A publication Critical patent/TW200930402A/zh
Application granted granted Critical
Publication of TWI455721B publication Critical patent/TWI455721B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G01N33/575—
    • G01N33/57595—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Claims (4)

  1. 一種人類白血球型抗原(HLA)-A*0201陽性者用癌疫苗組成物，係含有下列胜肽為特徵，WT1187 P1F胜肽：Phe Leu Gly Glu Gln Gln Tyr Ser Val(序列編號11)、WT1187 P2M胜肽：Ser Met Gly Glu Gln Gln Tyr Ser Val(序列編號16)、或WT1126 P1F胜肽：Phe Met Phe Pro Asn Ala Pro Tyr Leu(序列編號34)。
  2. 一種組成物，係含有下列胜肽的組成物，其係用於給藥至人類白血球型抗原(HLA)-A*0201陽性者，以治療或預防癌，WT1187 P1F胜肽：Phe Leu Gly Glu Gln Gln Tyr Ser Val(序列編號11)、WT1187 P2M胜肽：Ser Met Gly Glu Gln Gln Tyr Ser Val(序列編號16)、或WT1126 P1F胜肽：Phe Met Phe Pro Asn Ala Pro Tyr Leu(序列編號34)。
  3. 一種胜肽的用途，係用於製造人類白血球型抗原(HLA)-A*0201陽性者的癌的治療或預防藥，上述胜肽為WT1187 P1F胜肽：Phe Leu Gly Glu Gln Gln Tyr Ser Val(序列編號11)、WT1187 P2M胜肽：Ser Met Gly Glu Gln Gln Tyr Ser Val(序列編號16)、或 WT1126 P1F胜肽：Phe Met Phe Pro Asn Ala Pro Tyr Leu(序列編號34)。
  4. 一種胜肽，其係以下述序列定義者WT1187 P1F胜肽：Phe Leu Gly Glu Gln Gln Tyr Ser Val(序列編號11)、WT1187 P2M胜肽：Ser Met Gly Glu Gln Gln Tyr Ser Val(序列編號16)、或WT1126 P1F胜肽：Phe Met Phe Pro Asn Ala Pro Tyr Leu(序列編號34)。
TW97147299A 2007-12-05 2008-12-05 癌疫苗組合物 TWI455721B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007314552 2007-12-05

Publications (2)

Publication Number Publication Date
TW200930402A TW200930402A (en) 2009-07-16
TWI455721B true TWI455721B (zh) 2014-10-11

Family

ID=40717788

Family Applications (2)

Application Number Title Priority Date Filing Date
TW102139047A TWI504407B (zh) 2007-12-05 2008-12-05 癌疫苗組合物
TW97147299A TWI455721B (zh) 2007-12-05 2008-12-05 癌疫苗組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW102139047A TWI504407B (zh) 2007-12-05 2008-12-05 癌疫苗組合物

Country Status (12)

Country Link
US (5) US8557779B2 (zh)
EP (2) EP2228072B1 (zh)
JP (3) JP5478260B2 (zh)
KR (2) KR101610664B1 (zh)
CN (3) CN101888852B (zh)
AU (1) AU2008332278C1 (zh)
CA (3) CA2706907C (zh)
ES (2) ES2989864T3 (zh)
MX (1) MX2010006070A (zh)
RU (3) RU2682726C9 (zh)
TW (2) TWI504407B (zh)
WO (1) WO2009072610A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504407B (zh) * 2007-12-05 2015-10-21 癌免疫研究所股份有限公司 癌疫苗組合物

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
MX353165B (es) * 2010-08-24 2017-12-20 Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
SG10201602159VA (en) * 2011-02-11 2016-04-28 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
US9803246B2 (en) * 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
CA2846479A1 (en) 2011-09-14 2013-03-21 International Institute Of Cancer Immunology, Inc. Method for measuring anti-wt1 antibody
KR102020491B1 (ko) * 2011-10-28 2019-09-10 온코세라피 사이언스 가부시키가이샤 Ｔｏｐｋ 펩티드 및 이를 포함하는 백신
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
MX364732B (es) 2012-12-13 2019-05-06 Univ Pennsylvania Vacuna contra el tumor de wilms 1.
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2898099C (en) * 2013-01-15 2025-09-16 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 Peptides and Their Methods of Use
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CA2841014A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
JP6512567B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
CA2905588C (en) * 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
CA2907782C (en) 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
JP6634287B2 (ja) * 2013-05-13 2020-01-22 株式会社癌免疫研究所 免疫療法の臨床効果の予測法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
CN114949171A (zh) * 2014-12-11 2022-08-30 株式会社癌免疫研究所 血管生成性疾病的免疫疗法
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
JP6028253B2 (ja) * 2015-01-28 2016-11-16 学校法人北里研究所 癌細胞の検出方法及び癌細胞検出キット
CA2987247A1 (en) 2015-03-20 2016-09-29 The Trustees Of The University Of Pennsylvania Isg15 and its use as an adjuvant
JP6991969B2 (ja) 2015-11-20 2022-03-03 メモリアル スローン ケタリング キャンサー センター 癌を治療するための方法及び組成物
US20190025314A1 (en) 2016-01-11 2019-01-24 Janette Dixon Methods for determining tumour phenotypes
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
TWI851607B (zh) * 2018-10-05 2024-08-11 日商癌免疫研究所股份有限公司 良性腫瘤之預防或治療藥
TW202528332A (zh) 2019-02-28 2025-07-16 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
AU2021272616A1 (en) 2020-05-12 2022-12-15 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition for treating cancer
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
KR20250158315A (ko) 2024-04-30 2025-11-06 한림대학교 산학협력단 골육종용 암백신 항원단백질 및 이를 포함하는 암백신 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640458A1 (en) * 2003-06-27 2006-03-29 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
CN1762490A (zh) * 1998-07-31 2006-04-26 杉山治夫 基于癌抑制基因wt1的产物的癌抗原

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3904260B2 (ja) 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
AU765733B2 (en) * 1998-07-28 2003-09-25 Kyogo Itoh HLA-A2 restraint tumor antigen peptide originating in SART-1
KR100752065B1 (ko) * 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007516966A (ja) * 2003-12-01 2007-06-28 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 合成ｈｌａ結合ペプチド類似体及びその使用方法
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
US8540965B2 (en) 2005-07-29 2013-09-24 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
KR101610664B1 (ko) * 2007-12-05 2016-04-08 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 백신 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1762490A (zh) * 1998-07-31 2006-04-26 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
EP1640458A1 (en) * 2003-06-27 2006-03-29 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tanigaki N et al." HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products", Hum Immunol. 1994 Mar;39(3):155-62. Brett Trost et al." Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools", Immunome Research 2007, 3:5. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504407B (zh) * 2007-12-05 2015-10-21 癌免疫研究所股份有限公司 癌疫苗組合物

Also Published As

Publication number Publication date
CN101888852A (zh) 2010-11-17
CN101888852B (zh) 2017-02-08
US10426822B2 (en) 2019-10-01
EP2228072A4 (en) 2012-03-14
JP2016166223A (ja) 2016-09-15
US20170232089A1 (en) 2017-08-17
WO2009072610A1 (ja) 2009-06-11
US20140023670A1 (en) 2014-01-23
TW201406390A (zh) 2014-02-16
CA2940962C (en) 2018-07-24
US20190388529A1 (en) 2019-12-26
US9119801B2 (en) 2015-09-01
EP2228072B1 (en) 2018-06-13
RU2721574C2 (ru) 2020-05-20
JPWO2009072610A1 (ja) 2011-04-28
EP3384926B1 (en) 2024-10-09
US20160367649A1 (en) 2016-12-22
US8557779B2 (en) 2013-10-15
CA2881594A1 (en) 2009-06-11
CA2881594C (en) 2016-04-12
RU2013141923A (ru) 2015-03-20
CA2706907C (en) 2016-10-18
TWI504407B (zh) 2015-10-21
CA2706907A1 (en) 2009-06-11
JP6435286B2 (ja) 2018-12-05
JP2013241417A (ja) 2013-12-05
EP2228072A1 (en) 2010-09-15
CN103394079A (zh) 2013-11-20
AU2008332278B2 (en) 2013-06-13
CA2940962A1 (en) 2009-06-11
RU2013141920A (ru) 2015-03-20
TW200930402A (en) 2009-07-16
AU2008332278A1 (en) 2009-06-11
JP5478260B2 (ja) 2014-04-23
CN103394079B (zh) 2017-03-01
AU2008332278C1 (en) 2013-10-03
KR20100090710A (ko) 2010-08-16
ES2679127T3 (es) 2018-08-22
ES2989864T3 (es) 2024-11-28
JP5921494B2 (ja) 2016-05-24
KR101592855B1 (ko) 2016-02-12
US20110070251A1 (en) 2011-03-24
KR101610664B1 (ko) 2016-04-08
RU2682726C9 (ru) 2019-08-15
US11707512B2 (en) 2023-07-25
KR20150055091A (ko) 2015-05-20
CN105903006A (zh) 2016-08-31
MX2010006070A (es) 2010-12-06
RU2682726C2 (ru) 2019-03-22
EP3384926A1 (en) 2018-10-10
RU2010127298A (ru) 2012-01-10

Similar Documents

Publication Publication Date Title
TWI455721B (zh) 癌疫苗組合物
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
JP2007516966A5 (zh)
JP2012176978A5 (zh)
NZ602824A (en) Sparc binding peptides and uses thereof
US10363282B2 (en) Analogs of C5a and methods of using same
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ708990A (en) Method for activating helper t cell
JP2011250797A5 (zh)
JP2019533722A5 (zh)
PH12012500756A1 (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
JP2012506411A5 (zh)
WO2009033770A3 (en) Calcitonin c-terminal flanking peptide for use as a therapeutic agent
JPWO2019156137A5 (zh)
NO20053860L (no) COP 1 for behandling av inflammatorisk tarmsykdom.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP2017502003A5 (zh)
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
JP2017505772A5 (zh)
PH12015502005A1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
CN109153720A (zh) 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断
JP2020117504A5 (zh)
JP2009500045A5 (zh)
WO2016033432A9 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition